Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Tokyo Big Sight

Oct 18, 2026 9:30 AM - Oct 20, 2026 6:00 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

The 23rd DIA Japan Annual Meeting 2026

“Crossing Boundaries, Shaping a Future Beyond Imagination with Innovation.”

Overview

Click Here to View the Flyer

 
The 23rd DIA Japan Annual Meeting 2026 will be held at Tokyo Big-Sight from October 18 to 20, 2026.

The theme of this meeting is:
“Crossing Boundaries, Shaping a Future Beyond Imagination with Innovation.”

Today, the fields of healthcare and pharmaceutical development are undergoing a transformation of unprecedented proportions. Rapid advances in digital technologies and AI, diversification of drug discovery and development models, open innovation, regulatory reforms, patient-centric approaches, engagement of diverse stakeholders, and the pursuit of sustainability and social value are all progressing simultaneously—ushering in an era of change unlike any before.

 

Traditionally, medicine and healthcare have been confined to biological and chemical domains. In recent years, however, collaboration with engineering and IT has accelerated, and integration with human and social sciences—such as addressing ELSI (ethical, legal, and social issues)—has become indispensable.

The concept of “Neue Kombinationen” (literally  "new combination", rendered as "innovation"), proposed by economist Joseph Schumpeter, refers not merely to invention or technological innovation, but to the creative act of combining existing elements in new ways. Such “new combinations” drive discontinuous change—what Schumpeter called “creative destruction”—bringing new value to society and industry.

 

In today’s world, connecting knowledge and technologies across disciplines through “innovation ” is more critical than ever. While AI has dramatically improved the efficiency of information processing and output, what AI generates remains an extension of existing knowledge and patterns. Therefore, creative attempts to combine existing elements in unprecedented ways represent a uniquely human endeavor—one that may hold the key to shaping the future in the AI era.

 

At the 23rd DIA Japan Annual Meeting, we aim to create a forum where participants from diverse fields, roles, organizations, and countries come together to explore possibilities beyond imagination through “innovation” born of interdisciplinary collaboration. We hope that each participant will bring their expertise and experience, engage in discussion and cooperation across disciplines, and seize this opportunity to open new horizons in healthcare and pharmaceutical development.

Program Committee

  • Haruko  Yamamoto, MD, PHD
    Haruko Yamamoto, MD, PHD Executive Director
    National Cerebral and Cardiovascular Center, Japan
  • Miyoko  Yamauchi
    Miyoko Yamauchi Head, Human Capital Development Group
    CHUGAI PHARMACEUTICAL CO., LTD., Japan
  • Kasumi  Daidoji, PHD, RPH
    Kasumi Daidoji, PHD, RPH Associate Director, Clinical Planning & Development Dept., Medical Headquarters
    Eisai Company, Ltd., Japan
  • Kei  Fukuhara, MSC
    Kei Fukuhara, MSC Manager, Clinical Pharmacology
    Pfizer R&D Japan, Japan
  • Akiko  Ikeda, RPH
    Akiko Ikeda, RPH PRIMO, External Researcher/Consultant
    National Cancer Center, Japan
  • Masanari  Jinnouchi
    Masanari Jinnouchi CEO
    Peaceful Co., Ltd., Japan
  • Masaaki  Jitsu
    Masaaki Jitsu
    Bayer Yakuhin Ltd, Japan
  • Hiroyuki  Kanoh
    Hiroyuki Kanoh Senior Adviser, Laboratory & Office Group
    MITSUI FUDOSAN Co., LTD, Japan
  • Keiko  Katsui, PHD
    Keiko Katsui, PHD Division of Biomedical Ethics and Social Co-Creation
    Japan Agency for Medical Research and Development (AMED), Japan
  • Keiji  Kido
    Keiji Kido Associate director, Global Patients Safety and Solutions
    ELi Lilly Japan K.K., Japan
  • Takashi  Kimura, MS
    Takashi Kimura, MS Clinical Operation
    Pfizer R&D Japan G.K., Japan
  • Kentaro  Kogushi, PHD
    Kentaro Kogushi, PHD Head of Clinical Development Neurology-Psychiatry, Japan Development
    AbbVie GK, Japan
  • Suguru  Komenoi
    Suguru Komenoi Chief Reviewer, Offic of New Drug V
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Noriyuki  Kozawa
    Noriyuki Kozawa Deputy Coordination Director, Office of Medical Informatics and Science
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Misato  Kuwagaki, MS
    Misato Kuwagaki, MS Associate Director, Japan Data Sciences, Medical Sciences
    Eli Lilly Japan K.K., Japan
  • Ayano  Miyake
    Ayano Miyake Research Management
    St. Lukes International Hospital, Japan
  • Hiroki  Nagahama, MS
    Hiroki Nagahama, MS Director, Japan Safety Risk Management Lead, Clinical Safety & Pharmacovigilance
    GlaxoSmithKline K.K., Japan
  • Takashi  Nagakubo, PHD
    Takashi Nagakubo, PHD Principal Statistician, Biostatistics
    Glaxosmithkline K.K., Japan
  • Yukiko  Nishimura, PHD, MSC
    Yukiko Nishimura, PHD, MSC Director
    Advocacy Service for Rare and Intractable Diseases, Japan
  • Tomohiro  Obana
    Tomohiro Obana CRA Line Manager, Clinical Operation
    PPD SNBL, Japan
  • Ai  Okazaki, MT
    Ai Okazaki, MT Health Science Research & Development Center
    Institute of Science Tokyo Hospital, Japan
  • Chiharu  Onozaki
    Chiharu Onozaki Manager
    EPS International Holdings Co., Ltd., Japan
  • Yuki  Sasaki
    Yuki Sasaki Clinical Research Coordinator
    Hokkaido University Hospital, Japan
  • Marie  Shiga
    Marie Shiga
    Pfizer Japan Inc., Japan
  • Keisuke  Suzuki, PHD
    Keisuke Suzuki, PHD Director, Innovation Center for Translational Research
    National Center for Geriatrics and Gerontology, Japan
  • Akiko  Tamamori
    Akiko Tamamori Clinical Study Manager, Clinical Study Management Dept.
    Chugai Pharmaceutical Co., Ltd., Japan
  • MICHIYO  TANI
    MICHIYO TANI Vice President
    Planisware K.K., Japan
  • Naoyuki  Yabana, PHD
    Naoyuki Yabana, PHD Director, Office of Medical Devices I, Medical Devices Unit
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Manabu  YANAGISAWA, PHD
    Manabu YANAGISAWA, PHD Deputy General Manager,Clinical Research and Development Division, Development R
    Mochida Pharmaceutical Co., Ltd., Japan
  • Hiroto  Asou
    Hiroto Asou Reviewer, Office of New Drug IV
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Masahisa  Kamikura
    Masahisa Kamikura Pharmacist, Data Management Section/Data Management Division, Clinical Research
    National Cancer Center Hospital, Japan
  • Yusho  Kubota
    Yusho Kubota Oncology Clinical Development Department II
    A2 Healthcare Corporation, Japan
  • Eri  Matsunaga
    Eri Matsunaga R&D Quality Group, R&D & PV Quality Assurance Department
    Daiichi Sankyo Co., Ltd., Japan
  • Hideto  Minohara
    Hideto Minohara T-CReDO
    University of Tsukuba Hospital, Japan
  • Eri  Toyoshima
    Eri Toyoshima
    ZeeDia life science, Japan
  • Shinya  Watanabe
    Shinya Watanabe Reviewer (Epidemiology)
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Yukihiro  Matsuda, MSC
    Yukihiro Matsuda, MSC Director of Project Management
    Linical Japan, Japan
  • Keiko  Tsumori, MSC
    Keiko Tsumori, MSC Associate Principle Scientist, Medical Writing, Regulatory Affairs Area, Japan D
    MSD K.K., Japan
  • Mitsuhiro  Niimi, PHD
    Mitsuhiro Niimi, PHD Vice President & Managing Director, Japan
    DIA, Japan

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.